aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in Tampa, Florida, Oragenics Inc. is a biotech company dedicated to developing innovative bacterial-based therapies. The company's core mission is to address unmet medical needs through cutting-edge research and development. Oragenics focuses on creating antibiotics for infectious diseases and has expanded its portfolio to include NT-CoV2-1, an intranasal vaccine candidate for COVID-19. Additionally, the company is working on LPT3-04, a weight loss candidate, and SMaRT Replacement Therapy, a topical treatment aimed at preventing dental caries.
Oragenics has garnered attention from notable investors and industry experts, contributing to its growing reputation in the biotech field. The company has achieved significant milestones, including advancing its vaccine candidate for COVID-19 and securing funding for its various research initiatives. Through its innovative approach and commitment to addressing critical health issues, Oragenics has made a substantial impact on the medical community, particularly in the areas of infectious disease and dental health.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Antibiotics, Vaccines
Technology
Biotech
Tags
Healthtech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Oragenics Inc founded?
Oragenics Inc was founded in 1996.
Where is Oragenics Inc's headquarters located?
Oragenics Inc's headquarters is located in Los Angeles, CA, US.
When was Oragenics Inc's last funding round?
Oragenics Inc's most recent funding round was for $840k (USD) in August 2023.
How many employees does Oragenics Inc have?
Oragenics Inc has 5 employees as of Feb 6, 2024.
How much has Oragenics Inc raised to-date?
As of July 05, 2023, Oragenics Inc has raised a total of $99.7M (USD) since Aug 7, 2023.
Add Comparison
Total Raised to Date
$99.7M
USD
Last Update Aug 7, 2023
Last Deal Details
$840k
USD
Aug 7, 2023
Post Ipo Equity
Total Employees Over Time
5
As of Feb 2024
Oragenics Inc Address
Los Angeles,
California
90018
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts